TACR1

Substance-P receptor · P25103 · TACR1 on Sugi Atlas →

193,279 patent compounds predicted against TACR1, 98,208 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Lanepitant (SCHEMBL121512)	1.00	20/20
Spergualin (SCHEMBL155206)	1.00	20/20
Spergualin (SCHEMBL155207)	1.00	20/20
SCHEMBL119933	1.00	19/20
SCHEMBL156646	1.00	19/20
SCHEMBL119934	0.59	19/20
Aprepitant (SCHEMBL28850)	0.78	18/20
SCHEMBL175836	0.61	18/20
Fosaprepitant (SCHEMBL156378)	0.59	18/20
SCHEMBL156379	0.59	18/20
7-(3,5-Bis-Trifluoromethyl-Benzyl)-9-Methyl-5-P-Tolyl-8,9,10,11-Tetrahydro-7H-1,7,11A-Triaza-Cycloocta[B]Naphthalene-6,12-Dione (Atropisomeric Mix) (SCHEMBL122948)	1.00	17/20
Figopitant (SCHEMBL226054)	0.59	17/20
Osanetant (SCHEMBL119440)	1.00	16/20
SCHEMBL38042	0.51	16/20
SCHEMBL195121	0.46	10/20
SCHEMBL145681	0.41	10/20
SCHEMBL21419	0.51	8/20
SCHEMBL21921	0.54	7/20
Acetyltryptophan (SCHEMBL181483)	0.64	6/20
Acetyltryptophan (SCHEMBL181484)	0.64	6/20

Clinical trials — most relevant to TACR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3	PHASE4	COMPLETED
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea	PHASE3	COMPLETED
The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function	PHASE3	COMPLETED
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD	PHASE2	COMPLETED
Multi-day Doses in Prevention of Nausea and Emesis	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Effect of LY686017 on Alcohol Craving	PHASE2	COMPLETED
Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder	PHASE2	COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension	PHASE2	COMPLETED
Genetic Effects on Dopamine Response to an Opiate	PHASE2	COMPLETED
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ	PHASE1	COMPLETED
Medications Development for the Treatment of Cannabis Related Disorders	PHASE1	COMPLETED
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)	nan	RECRUITING
Role of Substance P in Post-Traumatic Stress Disorder	nan	COMPLETED
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.	nan	COMPLETED
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction	nan	COMPLETED
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression	nan	RECRUITING
Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology	nan	COMPLETED
Precision Medicine for Nociception, Sngception and Proprioception.	nan	RECRUITING
mGluR5 Imaging in ALS Using PET	nan	UNKNOWN
Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries	nan	UNKNOWN
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant	nan	COMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa	nan	COMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
The Effect of Oral Cryotherapy on Anticipatory, Acute and Late Nausea and Vomiting in Breast Cancer Patients	nan	COMPLETED
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis	nan	RECRUITING
Substance P-Induced Migraine Attacks Without Aura	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TACR1 binder may also engage these)

Protein	Name	Similarity
Q5DUB3	—	1.000	Q5DUB3 →
P30547	—	1.000	P30547 →
P30548	—	1.000	P30548 →
P14600	—	1.000	P14600 →
Q5DUB1	—	1.000	Q5DUB1 →
P47937	—	0.977	P47937 →
P16177	—	0.977	P16177 →
Q98982	—	0.961	Q98982 →
O97512	—	0.960	O97512 →
P30098	—	0.960	P30098 →
TACR3	Neuromedin-K receptor	0.959	landscape →
P83858	—	0.958	P83858 →
P83861	—	0.956	P83861 →
NMBR	Neuromedin-B receptor	0.946	landscape →
QRFPR	Pyroglutamylated RF-amide peptide receptor	0.945	landscape →
B2ZI34	—	0.944	B2ZI34 →
P24053	—	0.944	P24053 →
O54799	—	0.941	O54799 →
GRPR	Gastrin-releasing peptide receptor	0.935	landscape →
P21729	—	0.933	P21729 →
P52500	—	0.932	P52500 →
P30680	—	0.931	P30680 →
O18910	—	0.930	O18910 →
P42866	—	0.929	P42866 →
Q62805	—	0.928	Q62805 →
P56479	—	0.928	P56479 →
Q49LX6	—	0.927	Q49LX6 →
Q5IS39	—	0.927	Q5IS39 →
P34975	—	0.926	P34975 →
P33534	—	0.925	P33534 →